Advertisement
Screener

Neurogene Inc. (NGNE) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

2.5 / 5 stars · 25/51 Roast Me

Neurogene Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 1.37K shares, a 80.91% decline year-over-year.
  • Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 21.32K shares, a 1167.02% increase year-over-year.
  • Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 5.83K shares, a 34.15% decline year-over-year.
  • Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 6.02K shares, a 72.20% decline year-over-year.
  • Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 20.73K shares, a 77.62% decline from fiscal 2024.
  • Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 92.65K shares, a 355.34% increase from fiscal 2023.
  • Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 20.35K shares, a 44.25% decline from fiscal 2022.
  • Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 36.50K shares, a 70.78% decline from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month
2026-06-301.37K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
34.55K shares
derived: sum of 4 quarters · filed 2026-08-11
2026-03-3121.32K shares
10-Q · filed 2026-05-12
40.38K shares
derived: sum of 4 quarters · filed 2026-05-12
2025-12-315.83K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
20.73K shares
10-K · filed 2026-03-24
2025-09-306.02K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
23.76K shares
derived: sum of 4 quarters · filed 2025-11-13
2025-06-307.20K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11
39.40K shares
derived: sum of 4 quarters · filed 2025-08-11
2025-03-311.68K shares
10-Q · filed 2025-05-09
57.01K shares
derived: sum of 4 quarters · filed 2025-05-09
2024-12-318.86K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24
92.65K shares
10-K · filed 2025-03-24
2024-09-3021.66K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18
104.14K shares
derived: sum of 4 quarters · filed 2024-11-18
2024-06-3024.81K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09
82.48K shares
derived: sum of 4 quarters · filed 2024-08-09
2024-03-3137.33K shares
10-Q · filed 2024-05-10
57.68K shares
derived: sum of 4 quarters · filed 2024-05-10
2023-12-3120.35K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18
20.35K shares
10-K · filed 2024-03-18
2023-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
29.20K shares
derived: sum of 4 quarters · filed 2023-11-14
2023-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
0.00 shares
derived: sum of 4 quarters · filed 2023-11-14
2023-03-310.00 shares
10-Q · filed 2023-05-08
0.00 shares
derived: sum of 4 quarters · filed 2023-11-14
2022-12-3129.20K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20
36.50K shares
10-K · filed 2023-03-20
2022-09-30-29.20K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
7.86K shares
derived: sum of 4 quarters · filed 2023-11-14
2022-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
44.57K shares
derived: sum of 4 quarters · filed 2023-08-10
2022-03-3136.50K shares
10-Q · filed 2023-05-08
69.69K shares
derived: sum of 4 quarters · filed 2023-05-08
2021-12-31562.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
124.93K shares
10-K · filed 2022-03-01
2021-09-307.50K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
425.72K shares
derived: sum of 4 quarters · filed 2022-11-14
2021-06-3025.12K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
524.29K shares
derived: sum of 4 quarters · filed 2022-08-09
2021-03-3191.74K shares
10-Q · filed 2022-05-09
598.05K shares
derived: sum of 4 quarters · filed 2022-05-09
2020-12-31301.35K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25
882.62K shares
10-K · filed 2021-03-25
2020-09-30106.08K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
894.26K shares
derived: sum of 4 quarters · filed 2021-11-04
2020-06-3098.88K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
801.29K shares
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31376.31K shares
10-Q · filed 2021-05-12
702.40K shares
derived: sum of 4 quarters · filed 2021-05-12
2019-12-31312.99K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
326.09K shares
10-K · filed 2020-03-12
2019-09-3013.10K shares
10-Q · filed 2019-11-13
13.10K shares
derived: sum of 4 quarters · filed 2020-03-12
2019-06-300.00 shares
10-Q · filed 2019-08-01
0.00 shares
derived: sum of 4 quarters · filed 2020-03-12
2019-03-310.00 shares
10-Q · filed 2019-05-07
45.21K shares
derived: sum of 4 quarters · filed 2020-03-12
2018-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
64.94K shares
10-K · filed 2020-03-12
2018-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
72.44K shares
derived: sum of 4 quarters · filed 2018-11-07
2018-06-3045.21K shares
10-Q · filed 2018-08-08
72.66K shares
derived: sum of 4 quarters · filed 2018-08-08
2018-03-3119.73K shares
10-Q · filed 2018-05-08
69.01K shares
derived: sum of 4 quarters · filed 2018-05-08
2017-12-317.50K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12
49.28K shares
10-K · filed 2018-03-12
2017-09-30218.00 shares
10-Q · filed 2017-11-08
41.78K shares
derived: sum of 4 quarters · filed 2017-11-08
2017-06-3041.56K shares
10-Q · filed 2017-08-08
96.57K shares
derived: sum of 4 quarters · filed 2017-08-08
2017-03-310.00 shares
10-Q · filed 2017-05-09
55.66K shares
derived: sum of 4 quarters · filed 2017-05-09
2016-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09
55.66K shares
10-K · filed 2017-03-09
2016-09-3055.01K shares
10-Q · filed 2016-11-09
55.66K shares
derived: sum of 4 quarters · filed 2016-11-09
2016-06-30651.00 shares
10-Q · filed 2016-08-04
160.42K shares
derived: sum of 4 quarters · filed 2016-08-04
2016-03-310.00 shares
10-Q · filed 2016-05-10
163.86K shares
derived: sum of 4 quarters · filed 2016-05-10
2015-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14
191.88K shares
10-K · filed 2016-03-14
2015-09-30159.76K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10
2015-06-304.09K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06
2015-03-3128.02K shares
10-Q · filed 2015-05-12
2014-12-3186.00 shares
10-K · filed 2015-03-16
2014-09-3086.00 shares
10-Q · filed 2014-11-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
CorMedix Inc. (CRMD)United States$0.605B3.25
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Monopar Therapeutics (MNPR)United States$0.598B-34.82
Altimmune, Inc. (ALT)United States$0.593B-6.43
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76